Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to $28.9 million.

  • Heron Therapeutics' Gains from Investment Securities rose 1044.5% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 1044.5%. This contributed to the annual value of $8.2 million for FY2024, which is 4967.42% down from last year.
  • Heron Therapeutics' Gains from Investment Securities amounted to $28.9 million in Q3 2025, which was up 1044.5% from $29.7 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Gains from Investment Securities peaked at $31.3 billion during Q3 2023, and registered a low of $13000.0 during Q4 2023.
  • Over the past 5 years, Heron Therapeutics' median Gains from Investment Securities value was $20.4 million (recorded in 2022), while the average stood at $1.8 billion.
  • As far as peak fluctuations go, Heron Therapeutics' Gains from Investment Securities skyrocketed by 15266576.1% in 2023, and later crashed by 9991.65% in 2024.
  • Quarter analysis of 5 years shows Heron Therapeutics' Gains from Investment Securities stood at $2.1 million in 2021, then surged by 898.06% to $20.5 million in 2022, then plummeted by 99.94% to $13000.0 in 2023, then skyrocketed by 62653.85% to $8.2 million in 2024, then soared by 254.11% to $28.9 million in 2025.
  • Its Gains from Investment Securities stands at $28.9 million for Q3 2025, versus $29.7 million for Q2 2025 and $34000.0 for Q1 2025.